Clinical trial · Interventional
Prostate Cancer - Localized Adenocarcinoma Proton Therapy
A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With a Localized Prostate Adenocarcinoma
NCT03285815CI-TRIAL-00029571unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Adenocarcinoma | Prostate Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Proton Therapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Proton Therapy 60 CGE
- description
- 60 CGE (3CGE X 20) for 4wks
- interventionNames
- Device: Proton Therapy
- type
- EXPERIMENTAL
- label
- Proton Therapy 47 CGE
- description
- 47 CGE (4.7CGE X 10) for 2wks
- interventionNames
- Device: Proton Therapy
Primary outcomes (1)
- measure
- BCFFS
- timeFrame
- up to 5 years from a initial follow-up
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 * ECOG performance status:0-1 * Signed study specific informed consent prior to study entry. Exclusion Criteria: * Postoperative residual or recurrent tumor * Evidence of distant metastasis previous irradiation for the tumor in the same location * Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)
References
Publications (0)
Data not yet available
No reference posted for this study.